Recommended

Teva close to API business sale
First new IPF treatment in US for a decade
Webinar: Radiopharmaceuticals’ time-to-result challenge
AstraZeneca/Daiichi cancer drug boost
Takeda to move away from cell therapy
GSK appoints new CEO
news

FUJIFILM plans $1.2 billion investment in major US manufacturing facility

3
SHARES

Proposed additions to the cell culture manufacturing facility are set to make the site one of the largest cell culture biopharmaceutical CDMO facilities in North America.

FUJIFILM manufacturing Holly Springs

Credit: Sundry Photography / Shutterstock.com

FUJIFILM Corporation is planning to invest $1.2 billion to expand the planned FUJIFILM Diosynth Biotechnologies manufacturing facility in Holly Springs, North Carolina, US.

 

ACCESS your FREE COPY

 


This report addresses the key factors shaping pharmaceutical formulation, including regulation, QC and analysis.

Access the full report now to discover the techniques, tools and innovations that are transforming pharmaceutical formulation, and learn how to position your organisation for long-term success.

What you’ll discover:

  • Key trends shaping the pharmaceutical formulation sector
  • Innovations leading progress in pharmaceutical formulation and how senior professionals can harness their benefits
  • Considerations and best practices when utilising QbD during formulation of oral solid dosage forms
  • And more!

Don’t miss your chance to access this exclusive report ! Access now – it’s free

This news follows the organisation’s announcement of a $2 billion investment in the facility in March 2021. This additional financial boost totals the investment to over $3.2 billion, FUJIFILM confirmed.

Benefits of the manufacturing expansion

“This investment is an important step to further accelerate the growth of our biopharmaceutical CDMO business,” stated Teiichi Goto, President and Chief Executive Officer, Representative Director, FUJIFILM Corporation.

“Significant” large-scale production capacity will consequently be added to FUJIFILM Diosynth Biotechnologies’ global network.

The expansion means identical large-scale production facilities can be built in US and Europe to support integration drug manufacturing production “regardless of location”, FUJIFILM explained.

The new investment in the Holly Springs facility will “add 8 x 20,000 L mammalian cell culture bioreactors by 2028, to the already planned 8 x 20,000 L for bulk drug substance as part of the initial investment”.

This new facility allows for flexibility to expand with additional bioreactors to accommodate new projects, according to FUJIFILM.

Based on these aspects, when the facility is complete, the site will be one of the largest cell culture biopharmaceutical CDMO facilities in North America, FUJIFILM noted.

“We are pleased to continue investing to grow our cell culture manufacturing capabilities in North Carolina in anticipation of the growing outsourcing needs of biopharma companies,” commented Toshihisa Iida, Corporate Vice President of FUJIFILM Corporation and Chairman of FUJIFILM Diosynth Biotechnologies.

Biopharmaceuticals contributing to manufacturing outsourcing trend

Sustainability

To support the delivery of net-zero operations at the facility, FUJIFILM stated that all energy needs for operations is anticipated to be “100 percent offset through the use of renewable landfill gas, onsite solar and the 125,000 MWh of annual sustainable solar energy from a virtual power purchase agreement”.

Furthermore, the company shared that an additional 680 jobs will be created by 2031 due to the expansion.

Share via
Share via